Aclaris Therapeutics (DB:8AT) - Stock Price, News & Analysis

8AT Stock Overview

Aclaris Therapeutics, Inc., empresa biofarmacéutica en fase clínica, se dedica al desarrollo de nuevos fármacos candidatos para enfermedades inmunológico-inflamatorias en Estados Unidos.

About the company

8AT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Se prevé un crecimiento anual de los ingresos de 17.52%

Risk Analysis

Cotización muy volátil en los últimos 3 meses

Se prevé que los beneficios disminuyan una media de 6.8% al año durante los próximos 3 años.

No tiene una capitalización bursátil significativa (€91M)

Los accionistas se han diluido en el último año

+ 1 more risk

Aclaris Therapeutics, Inc. Competitors

Pierrel

DB:2FJ0

€92.8m

MPH Health Care

DB:93M1

€89.9m

Apontis Pharma

XTRA:APPH

€65.0m

SynBiotic

DUSE:SBX

€45.4m

Price History & Performance

Summary of all time highs, changes and price drops for Aclaris Therapeutics
Historical stock prices
Current Share Price	US$1.10
52 Week High	US$6.50
52 Week Low	US$0.59
Beta	0.23
1 Month Change	-8.04%
3 Month Change	6.11%
1 Year Change	n/a
3 Year Change	-95.43%
5 Year Change	-78.88%
Change since IPO	-96.26%

Recent updates

Shareholder Returns

	8AT	DE Pharmaceuticals	DE Market
7D	-1.5%	-6.0%	-1.3%
1Y	n/a	-31.5%	4.1%

Rentabilidad frente al sector: Datos insuficientes para determinar los resultados de 8AT en comparación con el sector German Pharmaceuticals .

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de 8AT frente al mercado German.

Price Volatility

Is 8AT's price volatile compared to industry and market?
8AT volatility
8AT Average Weekly Movement	17.5%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.7%
10% most volatile stocks in DE Market	9.8%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: El precio de las acciones de 8AT ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: 8ATha disminuido de 23% a 18% en el último año, pero sigue siendo superior al 75% de los valores de German.

About the Company

Founded	Employees	CEO	Website
2012	89	Neal Walker	https://www.aclaristx.com

Aclaris Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que se dedica al desarrollo de nuevos fármacos candidatos para enfermedades inmunológico-inflamatorias en Estados Unidos. La empresa opera a través de dos segmentos, Therapeutics y Contract Research. El segmento terapéutico se dedica a identificar y desarrollar terapias para hacer frente a importantes necesidades no cubiertas de enfermedades inmunoinflamatorias.

Aclaris Therapeutics, Inc. Fundamentals Summary

How do Aclaris Therapeutics's earnings and revenue compare to its market cap?
8AT fundamental statistics
Market cap	€77.89m
Earnings (TTM)	-€81.65m
Revenue (TTM)	€28.84m

2.7x

P/S Ratio

-1.0x

P/E Ratio

Is 8AT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8AT income statement (TTM)
Revenue	US$31.25m
Cost of Revenue	US$116.47m
Gross Profit	-US$85.22m
Other Expenses	US$3.27m
Earnings	-US$88.48m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.25
Gross Margin	-272.70%
Net Profit Margin	-283.15%
Debt/Equity Ratio	0%

How did 8AT perform over the long term?

See historical performance and comparison

8AT Stock Overview

Rewards

Risk Analysis

Aclaris Therapeutics, Inc. Competitors

DB:2FJ0

€92.8m

DB:93M1

€89.9m

XTRA:APPH

€65.0m

DUSE:SBX

€45.4m

Price History & Performance

Recent News & Updates

Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023

Full year 2023 earnings released: US$1.27 loss per share (vs US$1.33 loss in FY 2022)

Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Douglas Manion Steps Down as President and Member of the Board of Directors

Aclaris Therapeutics, Inc. Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Recent updates

Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023

Full year 2023 earnings released: US$1.27 loss per share (vs US$1.33 loss in FY 2022)

Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Douglas Manion Steps Down as President and Member of the Board of Directors

Aclaris Therapeutics, Inc. Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

New minor risk - Market cap size

Aclaris Therapeutics, Inc. Announces Top-Line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Third quarter 2023 earnings released: US$0.41 loss per share (vs US$0.30 loss in 3Q 2022)

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Co-Founder & Chairman recently sold €481k worth of stock

Full year 2022 earnings released: US$1.33 loss per share (vs US$1.60 loss in FY 2021)

Chief Business Officer recently sold €55k worth of stock

Aclaris Therapeutics, Inc. Announces Chief Financial Officer Changes

Insufficient new directors

Third quarter 2022 earnings released: US$0.30 loss per share (vs US$0.34 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2021)

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Executive Changes

Aclaris Therapeutics, Inc. Appoints Gail Cawkwell as Chief Medical Officer

Aclaris Therapeutics, Inc. Appoints Ian Anderson as Executive Vice President, Translational Research & Development

First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.57 loss in 1Q 2021)

Aclaris Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder recently sold €818k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Aclaris Therapeutics, Inc. Names James Loerop as Chief Business Officer, Effective January 31, 2022

Aclaris Therapeutics Provides R&D Update

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.25 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.28 loss in 2Q 2020)

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Microcap Value Index

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000009 million.

Aclaris Therapeutics, Inc. Announces Positive Preliminary Topline Data from Phase 2A Trial of ATI-1777

Co-Founder recently sold €212k worth of stock

First quarter 2021 earnings released: US$0.57 loss per share (vs US$0.37 loss in 1Q 2020)

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

Full year 2020 earnings released: US$1.20 loss per share (vs US$2.75 loss in FY 2019)

Revenue beats expectations

New 90-day high: €18.79

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Dynamic Index

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $95.964995 million.

Aclaris Therapeutics, Inc. Announces Positive Preliminary Topline Data from 12-Week Phase 2A Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

New 90-day high: €14.78

New 90-day high: €4.09

Aclaris Therapeutics, Inc. Announces Formation of New Scientific Advisory Board

Revenue beats expectations

Third quarter 2020 earnings released: US$0.25 loss per share

New 90-day high: €3.79

New 90-day high: €2.52

New 90-day high - €2.23

Earnings released

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Small Cap Completeness Index

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Index

Shareholder Returns

Price Volatility

About the Company